STOCK TITAN

BiomX (PHGE) Stock News, Aug 2022-May 2023

PHGE NYSE

Ticker history: PHGE became HLSQ (Tessera Defense and Homeland Security Inc.) on .

Historical ticker: BiomX Inc. changed its name to Tessera Defense and Homeland Security Inc. and began trading as HLSQ on September 11, 2026. PHGE news and SEC filings are retained here with their original names and dates. The profile below describes the earlier BiomX business.

BiomX Inc. (PHGE) news is centered on the company’s transition from a legacy phage therapy profile toward defense, security, critical infrastructure, and first-response technologies. Recent company announcements focus heavily on Zorronet, an AI defense technology subsidiary that develops command-and-control, computer vision, and autonomous surveillance systems.

PHGE news can include acquisition updates, material agreements, customer deployments, and operating details tied to Zorronet and DFSL. Zorronet-related coverage has included AI command-and-control software, secure on-premise and hybrid C5ISR deployments, mobile field-operator tools, and the use of cameras, sensors, drones, and IoT devices in integrated security environments.

Infrastructure and government-related items are also important for BiomX coverage. Company disclosures have discussed Zorronet’s work with Israel Railways, contracts with the Israel Defense Forces, and engagements involving government customers, Tier-1 OEMs such as Elbit Systems, and international clients. DFSL adds another news angle through LADAR-based detection systems for perimeter security, critical infrastructure, and counter-UAS markets.

BiomX news may also include SEC filing events, shareholder votes, governance changes, capital-structure disclosures, and operating results. Because the company has disclosed substantial doubt about its ability to continue as a going concern, financing and liquidity-related disclosures are also material to PHGE coverage. For investors tracking PHGE, the main news themes are defense technology acquisitions, operational deployments, critical infrastructure agreements, and the company’s remaining phage therapy background.

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.18%
Tags
private placement
-
Rhea-AI Summary

BiomX (PHGE) announced positive results from Part 1 of its Phase 1b/2a trial for BX004 targeting lung infections in cystic fibrosis (CF) patients. The treatment showed a significant bacterial load reduction of over 90% compared to placebo and no safety concerns. Enrollment for Part 2 is ongoing, with results expected in Q3 2023. Financially, BiomX reported a cash balance of $34.3 million as of Dec 31, 2022, down from $63.1 million the previous year. The company estimates its cash runway extends through mid-2024, supported by a $7.5 million private placement and a $5 million award from the Cystic Fibrosis Foundation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.24%
Tags
-
Rhea-AI Summary

BiomX Inc. (NYSE American: PHGE) has announced a conference call and live audio webcast on March 29, 2023, at 8:00 a.m. ET to discuss its fourth quarter and full year 2022 financial results along with business updates. The event will provide insights into the company's progress in developing natural and engineered phage therapies targeting pathogenic bacteria. Interested participants can join by dialing 1-877-407-0724 (U.S.) or 1-201-389-0898 (International), with the live and archived webcast available on BiomX's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.00%
Tags
conferences earnings date
Rhea-AI Summary

BiomX (NYSE American: PHGE) announced a securities purchase agreement to issue and sell 30,608,163 shares at $0.245 per share, raising approximately $7.5 million through a private investment in public equity (PIPE) financing. The financing will close in two parts: $1.5 million expected soon, and the remainder pending stockholder approval in Q2 2023. Proceeds will fund clinical development of BX004 for lung infections in cystic fibrosis patients and other programs. The shares are unregistered under the Securities Act and may not be sold in the U.S. without proper registration.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
private placement
-
Rhea-AI Summary

BiomX has reported positive results from Part 1 of its Phase 1b/2a trial for BX004, a phage therapy targeting chronic pulmonary infections in cystic fibrosis patients caused by Pseudomonas aeruginosa. The therapy was found to be safe and well-tolerated across all patients, with preliminary efficacy signals noted, including a significant reduction in bacterial burden of 1.42 log10 CFU/g compared to placebo. Patient dosing for Part 2 has commenced, with results expected in Q3 2023. This trial marks a significant advancement as the first double-blind placebo-controlled study showcasing the effectiveness of a phage-based treatment for this condition.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
-
Rhea-AI Summary

BiomX Inc. (NYSE American: PHGE) announced that CEO Jonathan Solomon will present at the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage on November 30, 2022. The virtual presentation is scheduled for 10:30 AM EST.

BiomX is innovating in the microbiome sector with novel phage therapies targeting specific pathogenic bacteria. The presentation will be available via the Company’s website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.50%
Tags
conferences
Rhea-AI Summary

BiomX (PHGE) has made progress in enrolling patients for its Phase 1/2 trial of BX004, targeting lung infections in cystic fibrosis. Following challenges in patient recruitment due to COVID-19, enrollment is now expected to complete by year-end, with initial results anticipated in Q1 2023. The company reported a cash balance of $41.5 million, sufficient to support operations until at least mid-2024. Notably, it received a $5 million Therapeutics Development Award from the Cystic Fibrosis Foundation, bolstering its financial position.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.38%
Tags
-
Rhea-AI Summary

BiomX Inc. (PHGE), a clinical-stage microbiome company, announced a conference call on November 9, 2022, at 8:00 a.m. ET to discuss its third quarter 2022 financial results and provide business updates. The conference will be accessible via phone or through a live audio webcast on the company's website. BiomX focuses on developing natural and engineered phage therapies aimed at treating chronic diseases by targeting specific pathogenic bacteria. More details can be found on their website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
conferences earnings date
-
Rhea-AI Summary

BiomX Inc. (NYSE American: PHGE), a clinical-stage microbiome company, announced that CEO Jonathan Solomon will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 7:00 AM EST. The conference runs from September 12-14, 2022. Presentations will be available on-demand, and the webcasts can be accessed via the BiomX Investors section post-event. The company focuses on developing phage therapies targeting pathogenic bacteria to treat chronic diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
conferences
Rhea-AI Summary

BiomX (PHGE) updates on its Phase 1b/2a trial for BX004, targeting lung infections in cystic fibrosis (CF), with results expected by Q3 2022. The company entered a collaboration with Boehringer Ingelheim to discover microbiome markers for inflammatory bowel disease. BiomX published significant research articles, including one in Cell, and has extended its cash runway through mid-2024 with a current cash position of $46.7 million. Despite a net loss of $7.5 million in Q2 2022, the company is focused on key milestones to enhance shareholder value.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.41%
Tags

FAQ

What is the current stock price of BiomX (PHGE)?

BiomX (PHGE) last closed at $1.85. The company now trades as HLSQ.